<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216735</url>
  </required_header>
  <id_info>
    <org_study_id>20070896</org_study_id>
    <secondary_id>GSK 11340</secondary_id>
    <nct_id>NCT01216735</nct_id>
  </id_info>
  <brief_title>Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers</brief_title>
  <official_title>Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis underlying the proposed study is that the blunted endothelium-dependent
      vasodilation seen in the airway of current smokers is also present in the brachial artery,
      and that the same inhaled corticosteroid (ICS) treatment regime that reversed endothelial
      function in the airway of current smokers will also restore endothelium-dependent relaxation
      in the brachial artery. Non-smokers will be used as controls and will not receive any
      intervention or treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cigarette smoking can lead to systemic endothelial dysfunction. Since the airway circulation
      is exposed to a high concentration of cigarette smoke constituents, we reasoned that airway
      vascular endothelial dysfunction could be present in healthy smokers without systemic
      endothelial dysfunction.

      The purpose of this study was to compare airway and systemic endothelial function and measure
      markers of systemic inflammation in lung-healthy current smokers. Since endothelial
      dysfunction in smokers has been related to systemic inflammation, we also investigated its
      response to an inhaled glucocorticosteroid (ICS).

      Vascular endothelial function was assessed in the airway by the airway blood-flow (Qaw)
      response to inhaled albuterol (ΔQaw) and in the extrapulmonary circulation by brachial
      arterial flow-mediated vasodilation (FMD). Venous blood was collected for C-reactive protein
      and IL-6.

      Qaw was measured with a noninvasive inhaled soluble gas uptake technique. The uptake of the
      gas from the anatomical deadspace reflecting airways perfused by the airway circulation was
      quantitated.

      Qaw was express as μL/min normalized for anatomical deadspace: μL/min/mL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Albuterol Induced Change in Qaw Before and After Fluticasone or Placebo</measure>
    <time_frame>3 weeks treatment period of ICS or placebo</time_frame>
    <description>Airway Blood flow (Qaw) will be measured before and 15 minutes after albuterol inhalation (delta Qaw).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated Brachial Vasodilation (FMD% Peak Delta)</measure>
    <time_frame>3 weeks of treatment</time_frame>
    <description>Flow-mediated vasodilation response in the brachial artery will be measured before and 15 minutes.after albuterol inhalation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Tobacco Abuse Smoke</condition>
  <arm_group>
    <arm_group_label>smokers, Fluticasone first, then Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI) . The subjects and the investigators will be blinded to the random choice of inhaler.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>smokers Placebo first, then Fluticasone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The current smokers will be given a 3-week treatment course of inhaled placebo MDI. The subjects and the investigators will be blinded to the random choice of inhaler.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>health non-smokers</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The healthy non-smokers will have only visit 1 and no intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>220 ug twice a day for 3 weeks</description>
    <arm_group_label>smokers, Fluticasone first, then Placebo</arm_group_label>
    <arm_group_label>smokers Placebo first, then Fluticasone</arm_group_label>
    <other_name>flovent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 3 weeks</description>
    <arm_group_label>smokers, Fluticasone first, then Placebo</arm_group_label>
    <arm_group_label>smokers Placebo first, then Fluticasone</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For both healthy non-smokers and healthy current smokers:

        normal spirometry Healthy current smokers: history of &gt;10 pack-year smoking

        Exclusion Criteria:

        Women of childbearing potential who do not use accepted birth control measures; pregnant
        and breast feeding women. Cardiovascular disease and/or use of cardiovascular medications.
        Subjects with known beta-adrenergic agonist or nitroglycerin intolerance. A physician
        diagnosis of chronic airway disease (asthma, COPD, bronchiectasis, cystic fibrosis).

        Acute respiratory infection within four weeks prior to the study. Use of any airway
        medication. FEV1 &lt; 80% of predicted and FEV1/FVC &lt; 0.7. A body mass index &gt; 30.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Wanner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Human Research Laboratory - University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mendes ES, Campos MA, Wanner A. Airway blood flow reactivity in healthy smokers and in ex-smokers with or without COPD. Chest. 2006 Apr;129(4):893-8. Erratum in: Chest. 2006 Jul;130(1):308.</citation>
    <PMID>16608935</PMID>
  </reference>
  <reference>
    <citation>Mendes ES, Horvath G, Rebolledo P, Monzon ME, Casalino-Matsuda SM, Wanner A. Effect of an inhaled glucocorticoid on endothelial function in healthy smokers. J Appl Physiol (1985). 2008 Jul;105(1):54-7. doi: 10.1152/japplphysiol.90334.2008. Epub 2008 May 8.</citation>
    <PMID>18467553</PMID>
  </reference>
  <reference>
    <citation>Wanner A, Campos MA, Mendes E. Airway blood flow reactivity in smokers. Pulm Pharmacol Ther. 2007;20(2):126-9. Epub 2006 Jan 18.</citation>
    <PMID>16414297</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <results_first_submitted>September 5, 2014</results_first_submitted>
  <results_first_submitted_qc>November 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2014</results_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Adam Wanner</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>smokers</keyword>
  <keyword>inhaled corticosteroids</keyword>
  <keyword>brachial flow</keyword>
  <keyword>airway blood flow</keyword>
  <keyword>albuterol</keyword>
  <keyword>spirometry</keyword>
  <keyword>endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>17 Non-smokers were enrolled to provide baseline measures and did not receive any intervention or treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluticasone First, Then Placebo</title>
          <description>The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI) or placebo. The subjects and the investigators will be blinded to the random choice of inhaler.
Fluticasone: 220 ug twice a day administered as a metered dose inhaled (MDI) or matching placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Fluticasone</title>
          <description>The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI) or placebo. The subjects and the investigators will be blinded to the random choice of inhaler.
Fluticasone: 220 ug twice a day administered as a metered dose inhaled (MDI) or matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (3 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (3 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (3 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>32 participants were enrolled divided in two groups smokers and controls</population>
      <group_list>
        <group group_id="B1">
          <title>Smokers</title>
          <description>The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI). The subjects and the investigators will be blinded to the random choice of inhaler.
Fluticasone: 220 ug twice a day administered as a metered dose inhaled (MDI)</description>
        </group>
        <group group_id="B2">
          <title>Non-smokers</title>
          <description>this group served as controls for baseline data. No intervention or treatment were assigned to this group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="36" upper_limit="58"/>
                    <measurement group_id="B2" value="38" lower_limit="32" upper_limit="54"/>
                    <measurement group_id="B3" value="42" lower_limit="32" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Airway blood flow (Qaw)</title>
          <units>um/ml/ul</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="3.7"/>
                    <measurement group_id="B2" value="46.2" spread="3.5"/>
                    <measurement group_id="B3" value="48.2" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Albuterol Induced Change in Qaw Before and After Fluticasone or Placebo</title>
        <description>Airway Blood flow (Qaw) will be measured before and 15 minutes after albuterol inhalation (delta Qaw).</description>
        <time_frame>3 weeks treatment period of ICS or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI). The subjects and the investigators will be blinded to the random choice of inhaler.
Fluticasone: 220 ug twice a day administered as a metered dose inhaled (MDI)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The current smokers will be given a 3-week treatment course of inhaled placebo MDI. The subjects and the investigators will be blinded to the random choice of inhaler.
Placebo: Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Albuterol Induced Change in Qaw Before and After Fluticasone or Placebo</title>
          <description>Airway Blood flow (Qaw) will be measured before and 15 minutes after albuterol inhalation (delta Qaw).</description>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="7.3"/>
                    <measurement group_id="O2" value="0.0" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Flow-mediated Brachial Vasodilation (FMD% Peak Delta)</title>
        <description>Flow-mediated vasodilation response in the brachial artery will be measured before and 15 minutes.after albuterol inhalation</description>
        <time_frame>3 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI). The subjects and the investigators will be blinded to the random choice of inhaler.
Fluticasone: 220 ug twice a day administered as a metered dose inhaled (MDI)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The current smokers will be given a 3-week treatment course of inhaled placebo MDI. The subjects and the investigators will be blinded to the random choice of inhaler.
Placebo: Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Flow-mediated Brachial Vasodilation (FMD% Peak Delta)</title>
          <description>Flow-mediated vasodilation response in the brachial artery will be measured before and 15 minutes.after albuterol inhalation</description>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0.6"/>
                    <measurement group_id="O2" value="4.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The AEs were collected during the duration of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone</title>
          <description>The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI). The subjects and the investigators will be blinded to the random choice of inhaler.
Fluticasone: 220 ug twice a day for 3 weeks
Placebo: Placebo for 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>The current smokers will be given a 3-week treatment course of inhaled placebo MDI. The subjects and the investigators will be blinded to the random choice of inhaler.
Fluticasone: 220 ug twice a day for 3 weeks
Placebo: Placebo for 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Wanner, MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>(305) 243-2568</phone>
      <email>awanner@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

